Gubra Strikes $2.225 Billion Deal with AbbVie for Obesity Treatment
Deal News | Mar 05, 2025 | Goodwin
Gubra A/S, listed on Nasdaq Copenhagen, has entered into a license agreement with AbbVie to develop a long-acting amylin analog for obesity treatment. AbbVie will gain global rights to develop and commercialize Gubra's GUB014295, currently in Phase 1 trials. The agreement includes an upfront payment of $350 million to Gubra, with potential additional payments of up to $1.875 billion, contingent on achieving certain development and sales milestones, plus tiered global sales royalties. This marks AbbVie's entry into the obesity treatment sector. Goodwin advised Gubra on this pivotal deal.
Sectors
- Pharmaceuticals and Biotechnology
- Healthcare
Geography
- Denmark – Gubra is a company based in Denmark and listed on Nasdaq Copenhagen.
- United States – AbbVie, the partner in the license agreement, is a leading global biopharmaceutical company headquartered in the United States.
Industry
- Pharmaceuticals and Biotechnology – The article discusses a license agreement between Gubra, a biotech firm, and AbbVie, a pharmaceutical company, for the development of an obesity treatment.
- Healthcare – The partnership aims to develop a treatment for obesity, which is a major health concern, highlighting its relevance to the healthcare industry.
Financials
- USD 350 million – Total upfront payment to Gubra as part of the license agreement.
- USD 1.875 billion – Potential additional payments based on development, commercial, and sales milestones.
- Not specified in USD – Tiered royalties on global net sales.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Gubra A/S | Target Company | Company | Gubra is a Danish company specializing in preclinical research services and peptide-based drug discovery. |
| AbbVie | Buyer | Company | AbbVie is a global biopharmaceutical company engaging in the agreement to develop a new obesity treatment. |
| Goodwin | Legal Advisor | Company | The legal firm advising Gubra on the license agreement with AbbVie. |
| Morag Peberdy | Advisor | Person | Member of Goodwin's team on the transaction. |
| Adam Bellack | Advisor | Person | Member of Goodwin's team on the transaction. |
| Lucy Charlton | Advisor | Person | Member of Goodwin's team on the transaction. |